- Home
- MESO vs JFR Comparison
MESO vs JFR Comparison
Compare MESO & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- JFR
- Stock Information
- Founded
- MESO 2004
- JFR 2004
- Country
- MESO Australia
- JFR United States
- Employees
- MESO N/A
- JFR N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- JFR Trusts Except Educational Religious and Charitable
- Sector
- MESO Health Care
- JFR Finance
- Exchange
- MESO Nasdaq
- JFR Nasdaq
- Market Cap
- MESO 1.3B
- JFR 1.1B
- IPO Year
- MESO N/A
- JFR N/A
- Fundamental
- Price
- MESO $11.06
- JFR $8.57
- Analyst Decision
- MESO Buy
- JFR
- Analyst Count
- MESO 4
- JFR 0
- Target Price
- MESO $18.00
- JFR N/A
- AVG Volume (30 Days)
- MESO 205.5K
- JFR 621.7K
- Earning Date
- MESO 08-28-2025
- JFR 01-01-0001
- Dividend Yield
- MESO N/A
- JFR 11.31%
- EPS Growth
- MESO N/A
- JFR N/A
- EPS
- MESO N/A
- JFR N/A
- Revenue
- MESO $5,670,000.00
- JFR N/A
- Revenue This Year
- MESO $178.09
- JFR N/A
- Revenue Next Year
- MESO $305.06
- JFR N/A
- P/E Ratio
- MESO N/A
- JFR N/A
- Revenue Growth
- MESO N/A
- JFR N/A
- 52 Week Low
- MESO $5.78
- JFR $7.61
- 52 Week High
- MESO $22.00
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- MESO 50.02
- JFR 74.32
- Support Level
- MESO $10.32
- JFR $8.47
- Resistance Level
- MESO $10.86
- JFR $8.59
- Average True Range (ATR)
- MESO 0.35
- JFR 0.04
- MACD
- MESO 0.00
- JFR 0.01
- Stochastic Oscillator
- MESO 45.04
- JFR 89.39
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.